Naibec "Discussing Peptide Pipeline Technology Transfer with Big Pharma at Bio USA"

[Asia Economy Reporter Hyunseok Yoo] Nivek announced on the 12th that it participated in the ‘2020 BIO International Convention BIO USA’ and held technology licensing discussions with global pharmaceutical companies regarding the anticancer drug delivery peptide platform ‘NIPEP-TPP’, the pulmonary fibrosis treatment ‘NIPEP-APF’, and the inflammatory bowel disease treatment ‘NIPEP-IBD’. In addition, research status presentations and corporate partnering related to the COVID-19 treatment ‘NIPEP-ACOV’ were also conducted.

Nivek’s peptide platform ‘NIPEP-TPP’ is a platform that maximizes effective drug delivery through selective targeting based on cell or tissue penetration. Joint research and development are underway with global pharmaceutical companies and European pharmaceutical companies, and progress review meetings related to this were held during the conference.

The pulmonary fibrosis treatment ‘NIPEP-APF’ has completed efficacy verification through safety tests at a European non-clinical trial institution (GLP) and preclinical animal models. Targeting entry into Phase 1 clinical trials in 2021, technology cooperation and licensing discussions are ongoing with global pharmaceutical companies based in Europe, and related meetings were held at this event.

Through the research status presentation section, Nivek announced the progress of its peptide pipeline and especially the research results related to the COVID-19 treatment ‘NIPEP-ACOV’. Multinational pharmaceutical companies such as Johnson & Johnson and Merck expressed great interest in the research results, leading to ‘corporate partnering’. Nivek is scheduled to be invited to the American Society for Infectious Diseases from the 15th to the 17th to present the dual-function research status of virus suppression and cytokine storm inhibition of the COVID-19 treatment ‘NIPEP-ACOV’.

A Nivek official stated, “We were concerned that the 2020 BIO USA, held in a non-face-to-face video conference format due to COVID-19, would make in-depth research discussions difficult, but rather, more data exchange and in-depth conversations took place without being constrained by the format.” He added, “Our company has continuously participated in international events such as BIO USA to maintain ongoing relationships with global pharmaceutical companies, and among them, we are continuing in-depth discussions with two companies. We will do our best to produce meaningful results.”

This content was produced with the assistance of AI translation services.